SynthesisBMJ open diabetes research & care2026
Prognostic significance of stress hyperglycemia ratio in patients undergoing percutaneous coronary intervention: a dose-response meta-analysis.
Synthesis in BMJ open diabetes research & care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStress hyperglycemia is common during percutaneous coronary intervention (PCI) and is associated with worse outcomes. The stress hyperglycemia ratio (SHR), which standardizes acute glucose levels to chronic glycemic status, may provide superior prognostic information compared with admission glucose alone.
objectiveTo systematically evaluate the association between SHR and clinical outcomes in PCI patients and to quantify the exposure-response relationship. DATA SOURCES: PubMed, Embase, Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov were searched from inception to August 5, 2025. STUDY SELECTION: Observational studies reporting SHR prior to PCI and subsequent clinical outcomes were included. DATA EXTRACTION: Two investigators independently extracted study characteristics, SHR definitions, and adjusted effect estimates. Risk of bias was assessed using ROBINS-I (Risk Of Bias In Non-randomized Studies of Interventions), and certainty of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation framework. DATA SYNTHESIS: Thirteen studies comprising 41 096 PCI patients were included. Elevated SHR was associated with increased risks of all-cause mortality, major adverse cardiac and cerebrovascular events (MACCE), cardiovascular mortality, recurrent myocardial infarction, and stroke, but not with repeat revascularization. Sensitivity analyses yielded consistent results. The dose-response analysis suggested an approximately linear dose-response pattern between SHR and MACCE. LIMITATIONS: Most studies were observational, SHR definitions varied, and residual confounding cannot be excluded. The limited number of studies restricted the interpretability of dose-response analyses.
conclusionsElevated SHR was associated with an increased risk of adverse outcomes after PCI. The dose-response analysis suggested an approximately linear dose-response pattern between SHR and MACCE. However, these findings should be interpreted cautiously given the observational nature of the evidence and the limited number of studies for certain analyses. PROSPERO REGISTRATION NUMBER: CRD420251045853.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.